0001127602-23-006770.txt : 20230223 0001127602-23-006770.hdr.sgml : 20230223 20230223162111 ACCESSION NUMBER: 0001127602-23-006770 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230215 FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dickinson Andrew D CENTRAL INDEX KEY: 0001310204 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 23659961 MAIL ADDRESS: STREET 1: 333 LAKESIDE DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2023-02-15 0000882095 GILEAD SCIENCES, INC. GILD 0001310204 Dickinson Andrew D GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY CA 94404 1 Chief Financial Officer Common Stock 2023-02-15 5 A 0 E 376 56.3805 A 105618 D The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2022 through February 15, 2023. This transaction is exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 16, 2022. /s/ Edward S. Son by Power of Attorney for Andrew D. Dickinson 2023-02-23